| Literature DB >> 32916976 |
Lidia Filip1, Florentina Duică1, Alina Prădatu1, Dragoș Crețoiu1,2, Nicolae Suciu1,3,4, Sanda Maria Crețoiu2, Dragoș-Valentin Predescu5, Valentin Nicolae Varlas6,7, Silviu-Cristian Voinea8.
Abstract
Endometriosis represents a frequently diagnosed gynecological affliction in the reproductive timespan of women, defined by symptoms ranging from pelvic pain to infertility. A complex interplay between the genetic profile, hormonal activity, menstrual cyclicity, inflammation status, and immunological factors define the phenotypic presentation of endometriosis. To date, imaging techniques represent the gold standard in diagnosing endometriosis, of which transvaginal ultrasonography and magnetic resonance imaging bring the most value to the diagnostic step. Current medical treatment options for endometriosis-associated infertility focus on either stimulating the follicular development and ovulation or on inhibiting the growth and development of endometriotic lesions. Techniques of assisted reproduction consisting of superovulation with in vitro fertilization or intrauterine insemination represent effective treatment alternatives that improve fertility in patients suffering from endometriosis. Emerging therapies such as the usage of antioxidant molecules and stem cells still need future research to prove the therapeutic efficacy in this pathology.Entities:
Keywords: endometriosis; etiopathogenesis; in vitro fertilization; infertility; treatment
Mesh:
Year: 2020 PMID: 32916976 PMCID: PMC7559069 DOI: 10.3390/medicina56090460
Source DB: PubMed Journal: Medicina (Kaunas) ISSN: 1010-660X Impact factor: 2.430
Figure 1As the theory of retrograde menstruation stipulates, the implantation of viable endometrial cells in the peritoneal cavity is facilitated by the constant reflux of endometrial debris during menstruation, leading to an inflammatory microenvironment in this anatomical compartment.
Pathophysiological processes altered by miRNA molecules, correlated with the modified expression in endometriosis suffering patients.
| Pathophysiological Processes | Downregulated | Upregulated | Published Studies |
|---|---|---|---|
| Cellular proliferation and | miR-543, miR-20a, miR-34c, miR-221, miR-222 | miR-142-5p, miR-146-a-5p, miR-1218, miR-940, miR-4634, miR-125a, miR-125b, miR-126, miR-143, miR-145 | [ |
| Angiogenesis | hsa-miR-483-5p, hsa-miR-483-5p, miR-16, miR-20a, miR-21, miR-141 | miR-202-3p, miR-424-5p, miR-556-3p, miR-449b-3p, miR-449b-3p, miR-556-3p, miR-29c-3phsa-miR-24, hsa-miR-885hsa-miR-26b, hsalet-7b, hsa-miR-18, miR-1, miR-194, miR-29c | [ |
| Hypoxia | miR-15b, miR-16, miR-199a, miR-20a, miR-200, miR-424, miR-130 | miR-20a, miR-20b, miR-155 | [ |
| Targeting inflammation | miR-16, miR-20a, miR-199a | miR-302a, miR200a | [ |